

# Prologue: 2013 Annual Meeting of the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA)

Wolf-Henning Boehncke and Dafna D. Gladman

**ABSTRACT.** The 2013 Annual Meeting of the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) was held in July 2013 in Toronto, Canada, and attended by rheumatologists, dermatologists, and representatives of biopharmaceutical companies and patient groups. We introduce the articles that summarize the meeting: A summary of a GRAPPA-organized Fellows Symposium adjacent to the 2013 European Academy of Dermatology and Venereology meeting in Istanbul; at the GRAPPA meeting proper, proceedings of a trainee symposium, where rheumatology fellows and dermatology residents presented their research; a summary of experiences and perspectives of psoriasis and psoriatic arthritis (PsA) research of 8 patient research partners with PsA who were invited to participate as delegates. Other presentations and discussions included an interactive session on composite measures of disease severity and response, including voting by GRAPPA members; a 3 part update of basic/translational/clinical science, including new bone formation, enthesitis pathophysiology, and comorbidity monitoring; a 3 part dermatology update on psoriasis outcome measures, the Brigham Scalp Nail Inverse Palmoplantar Psoriasis Composite Index, and large-scale databases; a short summary of the ongoing GRAPPA effort to update treatment guidelines for PsA; updates on several GRAPPA educational and rheumatology-related projects; and a discussion of clinical criteria to identify inflammatory arthritis, enthesitis, dactylitis, and spondylitis as distinguished from non-inflammatory conditions. (J Rheumatol 2014;41:1194–6; doi:10.3899/jrheum.140168)

## Key Indexing Terms:

PSORIASIS

COMORBIDITIES

PSORIATIC ARTHRITIS

RHEUMATOLOGY

OUTCOME MEASURES

MUSCULOSKELETAL INFLAMMATION

The 2013 annual meeting of the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) was held in Toronto, Canada. Investigators in the fields of rheumatology and dermatology, and representatives of biopharmaceutical companies or from patient service leagues (Table 1, Table 2) discussed individual and collaborative research and education initiatives in the fields of psoriasis and psoriatic arthritis (PsA). GRAPPA was originally formed in 2003, and the goals and list of core projects have been reported ([www.grappanetwork.org](http://www.grappanetwork.org))<sup>1,2,3,4</sup>.

Prior to the 2013 GRAPPA meeting, a reception was held honoring Dafna D. Gladman, Past President of GRAPPA, at

the University of Toronto on the occasion of the 35th anniversary of Toronto's Psoriatic Arthritis Program.

In a report from a Fellows Symposium adjacent to an October 2013 meeting of the European Academy of Dermatology and Venereology Congress in Istanbul, Turkey, 3 GRAPPA members, Wolf-Henning Boehncke (Geneva, Switzerland), Brian Kirby (Dublin, Ireland), and Diamant Thaci (Lübeck, Germany), summarized the proceedings of that meeting. Of 27 abstracts that were submitted and judged, 9 were chosen for discussion, including 5 that focused on comorbidities in patients with psoriasis or PsA<sup>5</sup>.

As in past years, the 2013 GRAPPA meeting began with a Trainees Symposium, chaired by Christopher Ritchlin (Rochester, New York, USA). Forty abstracts from dermatology and rheumatology trainees were submitted and ranked by a committee of reviewers. Five trainees with the highest-scored abstracts delivered oral presentations; the remainder presented posters that outlined their research. GRAPPA members provided feedback on how to transition current research projects to the next level<sup>6</sup>.

For the first time, 8 patients with PsA participated as full delegates at the 2013 GRAPPA meeting, where they were invited to provide their perspective for different sessions of

---

*From the Department of Dermatology, Geneva University Hospital, Geneva, Switzerland; and the University of Toronto, Toronto Western Research Institute, Toronto, Ontario, Canada.*

*Financial support to enable these meetings was provided in 2013 by AbbVie, Amgen, Bristol Myers Squibb, Celgene, Covagen, Janssen, Eli Lilly & Company, Novartis, Pfizer, and UCB.*

*W-H. Boehncke, MD, Department of Dermatology, Geneva University Hospital, and President, GRAPPA; D.D. Gladman, MD, FRCPC, Professor of Medicine, University of Toronto, Senior Scientist, Toronto Western Research Institute, and Chair, GRAPPA Publication Committee.*

*Address correspondence to Dr. Boehncke, Department of Dermatology, Geneva University Hospital, Rue Gabrielle-Perret-Gentil 4, CH1211, Geneva 14, Switzerland; E-mail: [wolf-henning.boehncke@hcuge.ch](mailto:wolf-henning.boehncke@hcuge.ch)*

Table 1. Composition of GRAPPA members.

Participant Type	Non-North American	North American	Total
Dermatologist	85	65	150
Rheumatologist	208	77	285
Geneticist	0	5	5
Methodologist	9	3	12
Radiologist	4	3	7
Others	8	4	12
Not filed	2	—	2
Patient group / government representative	7	3	10
Subtotals	323	160	483
Sponsors	62	72	134
Total	385	232	617

Table 2. GRAPPA executive and steering committee membership.

Executive Committee	Position
Wolf-Henning Boehncke	President
Philip Helliwell	Vice President
Philip Mease	Immediate Past President
Kristina Callis Duffin	Secretary
Alice Gottlieb	Member at-large
Arthur Kavanaugh	Member at-large
Oliver FitzGerald	Member at-large
Publications Committee	Position
Dafna Gladman	Chair
Steering Committee	City, Country
Adele O. Adebajo	Sheffield, England
April Armstrong	Davis, CA, USA
Valderilio Azevedo	Curitiba, Paraná, Brazil
Wolf-Henning Boehncke	Geneva, Switzerland
Kristina Callis Duffin	Salt Lake City, UT, USA
Alberto Cauli	Cagliari, Italy
Vinod Chandran	Toronto, ON, Canada
Laura Coates	Leeds, England
Kurt de Vlam	Leuven, Belgium
Oliver FitzGerald	Dublin, Ireland
Amit Garg	Worcester, MA, USA
Joel Gelfand	Philadelphia, PA, USA
Alice Gottlieb	Boston, MA, USA
Philip Helliwell	Leeds, England
Elaine Husni	Cleveland, OH, USA
Arthur Kavanaugh	La Jolla, CA, USA
Walter Maksymowycz	Edmonton, AB, Canada
Philip Mease	Seattle, WA, USA
Peter Nash	Brisbane, Queensland, Australia
Christopher Ritchlin	Rochester, NY, USA
Cheryl Rosen	Toronto, ON, Canada
Enrique Soriano	Buenos Aires, Argentina
Mona Ståhle	Stockholm, Sweden
Vibeke Strand	Portola Valley, CA, USA
Rafael Valle-Oñate	Bogotá, Colombia

the conference program. A summary is included of the presentations on patient participation in research, the experiences of these patient research partners, and plans to enhance the patient perspective in psoriasis and PsA research<sup>7</sup>.

Philip Helliwell (Leeds, UK) and Oliver FitzGerald (Dublin, Ireland) led a discussion of composite measures of disease severity and response for PsA, which included a vote by GRAPPA members on cutoffs for low/high disease activity in several scoring indices. Response criteria for the new composite indices have now been developed, but they require further validation and testing in other datasets<sup>8</sup>.

Three summaries of basic, translational, or clinical science issues important to GRAPPA members were discussed at the meeting. The first was presented by Georg Schett (Erlangen, Germany) on current research into the cytokine signature in PsA and its effects on new bone formation<sup>9</sup>. The second was a presentation by Dr. Ritchlin on enthesitis pathophysiology, which included enthesitis anatomy, its central role in PsA, and new data that may address the contribution of enthesial inflammation to key pathophysiologic pathways in the psoriatic joint<sup>10</sup>. A third presentation was by Dr. Boehncke on cardiovascular risk factors in psoriasis and PsA, with emphasis on current comorbidity screening guidelines for use by dermatologists and rheumatologists<sup>11</sup>.

Next, 3 dermatologic reports were presented. First, Alice Gottlieb (Boston, Massachusetts, USA) discussed the need for outcome measures for patients with dermatological conditions. She reported on the International Dermatology Outcome Measures group, which includes patients, physicians, payers, and pharmaceutical scientists, with a goal of developing outcome measures that address the needs of all involved<sup>12</sup>. Next, a group led by Joseph Merola (Boston) led a discussion of the Brigham Scalp Nail Inverse Palmoplantar Psoriasis Composite Index, as a complementary objective measure to the Psoriasis Area and Severity Index<sup>13</sup>. Finally, April Armstrong (Denver, Colorado, USA) led a discussion on large databases, including research networks, electronic medical records, and disease registries, that address real-world, clinically relevant dermatology questions<sup>14</sup>.

One of GRAPPA's central missions is to develop guidelines for the optimal treatment of patients with PsA. Although guidelines have previously been published, updated ones are necessary that reflect recent developments and ongoing research. A report was provided by Laura Coates (Leeds, UK), *et al* of the efforts to publish these new guidelines separately in 2014<sup>15</sup>.

GRAPPA members are also active in several educational areas in psoriasis and PsA. In an article by Kristina Callis Duffin (Salt Lake City, Utah, USA) *et al*, summaries are presented of the GRAPPA video project, the GRAPPA Educational Outreach Project, the Dermatology and Rheumatology Trainee Educational Initiative, and the GRAPPA Educational Slide Library<sup>16</sup>.

Several rheumatology projects were also summarized at the meeting. In an article by FitzGerald, *et al*, members were updated on progress made in a multicenter study to identify

soluble biomarkers for joint damage in the PsA BioDam Study, in developing classification criteria for arthritis mutilans, and in a proposal to study classification criteria for peripheral spondyloarthritis (e.g., PsA, reactive arthritis, inflammatory bowel disease-associated arthritis, and undifferentiated arthritis)<sup>17</sup>.

Finally, Philip Mease (Seattle, Washington, USA), *et al* described a research project to develop clinical criteria to aid in the identification of inflammatory arthritis, enthesitis, dactylitis, and spondylitis and to distinguish these from noninflammatory conditions. Breakout group exercises and planned project activities will eventually lead to the development of practical criteria to provide appropriate clinical care to patients with chronic inflammatory musculoskeletal conditions<sup>18</sup>.

A business meeting was held at the conclusion of the GRAPPA annual meeting, with discussions of action items. The next annual meeting will be held in New York, New York, USA, in July 2014.

## ACKNOWLEDGMENT

Special thanks go to Pam Love for her tireless organizational efforts, which kept the meeting running smoothly; and to Linda Melvin, writer/editor for GRAPPA 2013 papers.

## REFERENCES

1. Mease PJ, Gladman DD. Prologue: 2009 Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA). *J Rheumatol* 2011;38:522-5.
2. Mease PJ, Gladman DD. Prologue: 2010 Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA). *J Rheumatol* 2012;39:391-3.
3. Mease PJ, Gladman DD. Prologue: 2011 Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA). *J Rheumatol* 2012;39:2181-3.
4. Mease PJ, Boehncke WH, Gladman DD. Prologue: 2012 Annual Meeting of the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA). *J Rheumatol* 2013;40:1407-9.
5. Boehncke W-H, Kirby B, Thaci D. GRAPPA Fellows Symposium Adjacent to the European Academy of Dermatology and Venereology (EADV) Congress, Istanbul, 2013: A meeting report. *J Rheumatol* 2014;41:1197-9.
6. Szentpetery A, Johnson MN, Ritchlin CT. GRAPPA Trainees Symposium 2013: A report from the GRAPPA 2013 annual meeting. *J Rheumatol* 2014;41:1200-5.
7. de Wit M, Campbell W, FitzGerald O, Gladman DD, Helliwell PS, James J, et al. Patient participation in psoriasis and psoriatic arthritis outcome research: A report from the GRAPPA 2013 annual meeting. *J Rheumatol* 2014;41:1206-11.
8. Helliwell PS, FitzGerald O, Fransen J. Composite disease activity and responder indices for psoriatic arthritis: development of cut-offs for both disease activity states and response: A report from the GRAPPA 2013 annual meeting. *J Rheumatol* 2014;41:1212-7.
9. Schett G. Bone formation in psoriatic arthritis: A report from the GRAPPA 2013 annual meeting. *J Rheumatol* 2014;41:1218-9.
10. Ritchlin CT. Psoriatic enthesitis: An update from the GRAPPA 2013 annual meeting. *J Rheumatol* 2014;41:1220-3.
11. Boehncke W-H. GRAPPA 2013 basic/translational/clinical science update: Comorbidity monitoring. A report from the GRAPPA 2013 annual meeting. *J Rheumatol* 2014;41:1224-6.
12. Gottlieb AB, Armstrong AW, Christensen R, Garg A, Callis Duffin K, Boehncke W-H, et al. The International Dermatology Outcome Measures (IDEOM) Initiative as applied to psoriatic disease outcomes: A report from the GRAPPA 2013 annual meeting. *J Rheumatol* 2014;41:1227-9.
13. Patel M, Liu SW, Qureshi A, Merola JF. The Brigham Scalp Nail Inverse Palmoplantar Psoriasis Composite Index (B SNIP): A novel index to capture all non-plaque-psoriasis subsets: A report from the GRAPPA 2013 annual meeting. *J Rheumatol* 2014;41:1230-2.
14. Armstrong AW, Gelfand JM, Garg A. Outcomes research in psoriasis and psoriatic arthritis using large databases and research networks: A report from the GRAPPA 2013 annual meeting. *J Rheumatol* 2014;41:1233-6.
15. Coates LC, Ritchlin CT, Kavanaugh AF. GRAPPA Treatment recommendations: An update from the GRAPPA 2013 annual meeting. *J Rheumatol* 2014;41:1237-9.
16. Callis Duffin K, Garg A, Armstrong AW, Helliwell PS, Mease PJ. Psoriasis and psoriatic arthritis educational initiatives: An update from the 2013 GRAPPA annual meeting. *J Rheumatol* 2014;41:1240-3.
17. FitzGerald O, Mease PJ, Helliwell PS, Chandran V. GRAPPA 2013 annual meeting, rheumatology updates: psoriatic arthritis (PsA) biomarker project, arthritis mutilans, PsA-peripheral spondyloarthritis epidemiology project. *J Rheumatol* 2014; 41:1244-8.
18. Mease PJ, Garg A, Helliwell PS, Park JJ, Gladman DD. Development of criteria to distinguish inflammatory from noninflammatory arthritis, enthesitis, dactylitis, and spondylitis: A report from the GRAPPA 2013 annual meeting. *J Rheumatol* 2014;41:1249-51.